NCT06863480

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

THRIVE: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Florida · Academic / Other
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

Detailed description

This is a prospective single-arm, single-center, open-label Phase 1 trial of tocilizumab-aazg 6mg/kg IV infusion drip on Day 0 in patients with aneurysmal subarachnoid hemorrhage. The trial is designed to demonstrate safety and to detect a signal that tocilizumab-aazg prevents delayed cerebral ischemia in these patients.

Conditions

• Aneurysmal Subarachnoid Hemorrhage
• Delayed Cerebral Ischemia

Interventions

Type	Name	Description
DRUG	tocilizumab-aazg (TYENNE)	A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.

Timeline

• Start date: 2026-03-02
• Primary completion: 2028-07-30
• Completion: 2028-10-30
• First posted: 2025-03-07
• Last updated: 2026-03-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study